{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:29:34Z","timestamp":1770330574020,"version":"3.49.0"},"reference-count":49,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"unspecified","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["R01HL157533"],"award-info":[{"award-number":["R01HL157533"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,3,20]]},"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sarcoidosis is a pulmonary and systemic granulomatous disease with a wide range of potential outcomes, from spontaneous resolution to end-stage organ damage and death. Currently, clinicians have no easy-to-use risk stratification tools for important clinical outcomes in sarcoidosis, such as progressive lung disease. This study will address two clinical practice needs: (1) development of a risk calculator that provides an estimate of the likelihood of pulmonary progression in sarcoidosis patients during the follow-up period and (2) determine the optimal interval for serial clinical monitoring (eg, 6, 12, 18 months) using these risk prediction tools.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The Risk Indicators of Sarcoidosis Evolution-Unified Protocol study is a National Institutes of Health-sponsored, longitudinal observational study of adults with pulmonary sarcoidosis who will be enrolled at five US tertiary care centres. Participants will be evaluated at approximately 6-month intervals for up to 60 months with collection of lung function, blood samples and clinical data. The target sample size is 557 and the primary objective is to determine which clinical features measured during a routine clinic visit carry the most prognostic information for predicting clinical progression of pulmonary sarcoidosis over the follow-up period. The primary outcome measure will be quantified by a clinically meaningful change in forced vital capacity, forced expiratory volume in 1 s or diffusing capacity of the lung for carbon monoxide. The secondary objective is to determine if blood biomarkers measured during a routine clinic visit can improve the risk assessment modelling for progression of pulmonary sarcoidosis over the follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study protocol has been approved by the Institutional Review Boards at each centre and the reliance Institutional Review Board overseeing the study (WCG, Protocol #20222400). Participants will provide informed consent prior to enrolment. Results will be disseminated via publication in a relevant peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05567133\">NCT05567133<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-071607","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T13:23:13Z","timestamp":1680528193000},"page":"e071607","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Risk Indicators of Sarcoidosis Evolution-Unified Protocol (RISE-UP): protocol for a multi-centre, longitudinal, observational study to identify clinical features that are predictive of sarcoidosis progression"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05567133","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Wonder P","family":"Drake","sequence":"first","affiliation":[{"name":"Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA"},{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Connie","family":"Hsia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UT Southwestern Medical School, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lobelia","family":"Samavati","sequence":"additional","affiliation":[{"name":"Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Cardenas","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola G","family":"Gianella","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, UT Southwestern Medical School, Dallas, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Boscardin","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-3622","authenticated-orcid":false,"given":"Laura L","family":"Koth","sequence":"additional","affiliation":[{"name":"Department of Medicine and Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"2025121220593780000_13.4.e071607.1","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(22)01656-7","article-title":"Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in england, northern ireland, scotland, and wales","volume":"400","author":"Agrawal","year":"2022","journal-title":"Lancet"},{"key":"2025121220593780000_13.4.e071607.2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/MCP.0000000000000612","article-title":"Advanced sarcoidosis","volume":"25","author":"Baughman","year":"2019","journal-title":"Curr Opin Pulm Med"},{"key":"2025121220593780000_13.4.e071607.3","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects","volume":"11","author":"Kraaijvanger","year":"2020","journal-title":"Front Immunol"},{"key":"2025121220593780000_13.4.e071607.4","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2016.1196135"},{"key":"2025121220593780000_13.4.e071607.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1165\/rcmb.2017-0344ED","article-title":"Biomarkers in sarcoidosis: can microRNAs fill the gap?","volume":"58","author":"Bonham","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2025121220593780000_13.4.e071607.6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jjcc.2018.08.001","article-title":"MicroRNAs as biomarkers for cardiac sarcoidosis: no matter how small","volume":"72","author":"Umei","year":"2018","journal-title":"J Cardiol"},{"key":"2025121220593780000_13.4.e071607.7","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/1744666X.2019.1568240","article-title":"Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis","volume":"15","author":"Ramos-Casals","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2025121220593780000_13.4.e071607.8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1586\/14737175.2015.1037288","article-title":"Neurosarcoidosis: diagnosis, therapy and biomarkers","volume":"15","author":"Bagnato","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"2025121220593780000_13.4.e071607.9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/MCP.0000000000000306","article-title":"Biomarkers in sarcoidosis: the contribution of system biology","volume":"22","author":"Carleo","year":"2016","journal-title":"Curr Opin Pulm Med"},{"key":"2025121220593780000_13.4.e071607.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2015.08.005"},{"key":"2025121220593780000_13.4.e071607.11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/MCP.0000000000000716","article-title":"Molecular profiling in sarcoidosis","volume":"26","author":"Arger","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"2025121220593780000_13.4.e071607.12","doi-asserted-by":"crossref","first-page":"102462","DOI":"10.1016\/j.autrev.2020.102462","article-title":"Immune response biomarkers as indicators of sarcoidosis presence, prognosis, and possible treatment: an immunopathogenic perspective","volume":"19","author":"Tarasidis","year":"2020","journal-title":"Autoimmun Rev"},{"key":"2025121220593780000_13.4.e071607.13","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7163\/ab1284","article-title":"The role of measuring exhaled breath biomarkers in sarcoidosis: a systematic review","volume":"13","author":"Terrington","year":"2019","journal-title":"J Breath Res"},{"key":"2025121220593780000_13.4.e071607.14","first-page":"393","article-title":"Search for biomarkers of neurosarcoidosis by proteomic analysis of cerebrospinal fluid","volume":"75","author":"Taibi","year":"2017","journal-title":"Ann Biol Clin (Paris)"},{"key":"2025121220593780000_13.4.e071607.15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/MCP.0000000000000705","article-title":"Advanced pulmonary sarcoidosis","volume":"26","author":"Patel","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"2025121220593780000_13.4.e071607.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2008.03.006"},{"key":"2025121220593780000_13.4.e071607.17","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.3.922"},{"key":"2025121220593780000_13.4.e071607.18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025121220593780000_13.4.e071607.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2020.08.042"},{"key":"2025121220593780000_13.4.e071607.20","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MCP.0000000000000080","article-title":"Morbidity and mortality in sarcoidosis","volume":"20","author":"Gerke","year":"2014","journal-title":"Curr Opin Pulm Med"},{"key":"2025121220593780000_13.4.e071607.21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ccm.2015.08.012","article-title":"Severe sarcoidosis","volume":"36","author":"Kouranos","year":"2015","journal-title":"Clin Chest Med"},{"key":"2025121220593780000_13.4.e071607.22","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American thoracic society\/european respiratory society\/world association of sarcoidosis and other granulomatous disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025121220593780000_13.4.e071607.23","first-page":"19","article-title":"The WASOG sarcoidosis organ assessment instrument: an update of a previous clinical tool","volume":"31","author":"Judson","year":"2014","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025121220593780000_13.4.e071607.24","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00034805"},{"key":"2025121220593780000_13.4.e071607.25","doi-asserted-by":"crossref","first-page":"00016","DOI":"10.1183\/13993003.00016-2016","article-title":"2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung","volume":"49","author":"Graham","year":"2017","journal-title":"Eur Respir J"},{"key":"2025121220593780000_13.4.e071607.26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1515\/jomb-2017-0041","article-title":"Association between vitamin D deficiencies in sarcoidosis with disease activity, course of disease and stages of lung involvements","volume":"37","author":"Kiani","year":"2018","journal-title":"J Med Biochem"},{"key":"2025121220593780000_13.4.e071607.27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.0954-6820.1979.tb13507.x","article-title":"Prognostic significance of lymphopenia in sarcoidosis","volume":"206","author":"Selroos","year":"1979","journal-title":"Acta Med Scand"},{"key":"2025121220593780000_13.4.e071607.28","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.595077","article-title":"Unsupervised clustering reveals sarcoidosis phenotypes marked by a reduction in lymphocytes relate to increased inflammatory activity on 18FDG-PET\/CT","volume":"8","author":"Vagts","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025121220593780000_13.4.e071607.29","doi-asserted-by":"crossref","first-page":"106115","DOI":"10.1016\/j.rmed.2020.106115","article-title":"SIL-2R levels predict the spontaneous remission in sarcoidosis","volume":"171","author":"Zhou","year":"2020","journal-title":"Respir Med"},{"key":"2025121220593780000_13.4.e071607.30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.124.1.186"},{"key":"2025121220593780000_13.4.e071607.31","doi-asserted-by":"crossref","DOI":"10.3390\/biom8030084","article-title":"Ykl-40, soluble IL-2 receptor, angiotensin converting enzyme and C-reactive protein: comparison of markers of sarcoidosis activity","volume":"8","author":"Uysal","year":"2018","journal-title":"Biomolecules"},{"key":"2025121220593780000_13.4.e071607.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1975"},{"key":"2025121220593780000_13.4.e071607.33","first-page":"41","article-title":"The clinical value of serum soluble interleukin-2 receptor in pulmonary sarcoidosis","volume":"34","author":"Ogata-Suetsugu","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025121220593780000_13.4.e071607.34","doi-asserted-by":"publisher","DOI":"10.1080\/00365510701854975"},{"key":"2025121220593780000_13.4.e071607.35","doi-asserted-by":"publisher","DOI":"10.1373\/49.9.1510"},{"key":"2025121220593780000_13.4.e071607.36","doi-asserted-by":"publisher","DOI":"10.1007\/PL00007637"},{"key":"2025121220593780000_13.4.e071607.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.12.004"},{"key":"2025121220593780000_13.4.e071607.38","first-page":"331","article-title":"Predictive value of C-reactive protein and clinically relevant baseline variables in sarcoidosis","volume":"33","author":"McDonnell","year":"2016","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025121220593780000_13.4.e071607.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.04.005"},{"key":"2025121220593780000_13.4.e071607.40","doi-asserted-by":"crossref","first-page":"105822","DOI":"10.1016\/j.rmed.2019.105822","article-title":"CXCL9 and CXCL10 are differentially associated with systemic organ involvement and pulmonary disease severity in sarcoidosis","volume":"161","author":"Arger","year":"2020","journal-title":"Respir Med"},{"key":"2025121220593780000_13.4.e071607.41","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200211-1311OC"},{"key":"2025121220593780000_13.4.e071607.42","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141182"},{"key":"2025121220593780000_13.4.e071607.43","first-page":"204","article-title":"Two year prognosis of sarcoidosis: the ACCESS experience","volume":"20","author":"Judson","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2025121220593780000_13.4.e071607.44","doi-asserted-by":"publisher","DOI":"10.1093\/restud\/rdt044"},{"key":"2025121220593780000_13.4.e071607.45","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/69.1.239"},{"key":"2025121220593780000_13.4.e071607.46","unstructured":"EW S . Clinical prediction models A practical approach to development, validation, and updating. 2019."},{"key":"2025121220593780000_13.4.e071607.47","doi-asserted-by":"crossref","unstructured":"Blanche P , Latouche A , Viallon V . Time-dependent AUC with right-censored data:a survey. In: Risk Assessment and Evaluation of Predictions. 2013.","DOI":"10.1007\/978-1-4614-8981-8_11"},{"key":"2025121220593780000_13.4.e071607.48","doi-asserted-by":"publisher","DOI":"10.1002\/sim.8570"},{"key":"2025121220593780000_13.4.e071607.49","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m441","article-title":"Calculating the sample size required for developing a clinical prediction model","volume":"368","author":"Riley","year":"2020","journal-title":"BMJ"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-071607","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:59:45Z","timestamp":1765601985000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-071607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,3]]},"published-print":{"date-parts":[[2023,4]]}},"alternative-id":["10.1136\/bmjopen-2023-071607"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-071607","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4]]}}}